Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium 223 for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT Number:
NCT03574571
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Prostate
Study Objectives:
This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in
combination with radium-223 in subjects with mCRPC. The primary objective is to compare overall survival for subjects treated with docetaxel versus subjects treated with
docetaxel plus radium-223.
Study Documents
(MUSC NetID required for document access)